ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines
BioMed Research International · 2023
DOI: 10.1155/2023/7891753 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioMed Research International, 2023. Verfasst von Rakkreat Wikiniyadhanee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Program in Translational Medicine, Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bang Phli, S…. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Council of Thailand, Mahidol University.
Abstract (Originalsprache)
The inhibition of poly(ADP‐ribose) polymerases (PARPs) and ataxia telangiectasia and Rad3‐related (ATR) would be an alternative approach for cancer treatments. The aim of this study is to investigate the synergy of the different combinations of PARP inhibitors (olaparib, talazoparib, or veliparib) and ATR inhibitor AZD6738. A drug combinational synergy screen that combines olaparib, talazoparib, or veliparib with AZD6738 was performed to identify the synergistic interaction, and the combination index was calculated to verify synergy. TK6 isogenic cell lines with defects in different DNA repair genes were used as a model. Cell cycle analysis, micronucleus induction, and focus formation assays of serine‐139 phosphorylation of the histone variant H2AX demonstrated that AZD6738 diminished G2/M checkpoint activation induced by PARP inhibitors and allowed DNA damage‐containing cells to continue dividing, leading to greater increases in micronuclei as well as double‐strand DNA breaks in mitotic cells. We also found that AZD6738 was likely to potentiate cytotoxicity of PARP inhibitors in homologous recombination repair deficiency cell lines. AZD6738 sensitized more genotypes of DNA repair‐deficient cell lines to talazoparib than to olaparib and veliparib, respectively. The combinational approach of PARP and ATR inhibition to enhance response to PARP inhibitors could expand the utility of PARP inhibitors to cancer patients without BRCA1/2 mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Program in Translational Medicine, Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bang Phli, Samutprakarn 10540, Thailand.
- Research Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
- Shenzhen University School of Medicine, Shenzhen, Guangdong 518054, China.
- Department of Radiation Genetics, Medical School, Kyoto University, Kyoto 606-8501, Japan.
ORCID-Profile: Rakkreat Wikiniyadhanee, Tassanee Lerksuthirat, Wasana Stitchantrakul, Sermsiri Chitphuk, Shunichi Takeda, Donniphat Dejsuphong
Förderung
- National Research Council of Thailand
- Mahidol University
Zitieren
APA
Wikiniyadhanee, R., Lerksuthirat, T., Stitchantrakul, W., Chitphuk, S., Takeda, S., & Dejsuphong, D. (2023). ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines. BioMed Research International. https://doi.org/10.1155/2023/7891753
Vancouver
Wikiniyadhanee R, Lerksuthirat T, Stitchantrakul W, Chitphuk S, Takeda S, Dejsuphong D. ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines. BioMed Research International. 2023. doi:10.1155/2023/7891753
BibTeX
@article{Wikiniyadhanee2023,
author = {Wikiniyadhanee, Rakkreat and Lerksuthirat, Tassanee and Stitchantrakul, Wasana and Chitphuk, Sermsiri and Takeda, Shunichi and Dejsuphong, Donniphat},
title = {ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines},
journal = {BioMed Research International},
year = {2023},
doi = {10.1155/2023/7891753}
}
EUVIMED